Stock STIM NEURONETICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Neuronetics, Inc.

Equities

STIM

US64131A1051

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
1.92 USD +1.05% Intraday chart for Neuronetics, Inc. -11.93% -33.79%
May. 15 Humana Is First Commercial Payer to Address TMS Therapy Coverage for Adolescents CI
May. 14 William Blair Upgrades Neuronetics to Outperform From Market Perform MT

Evolution of the average Target Price on Neuronetics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

849f4ade58f6bf5a80.0ZcUToUjs4Dk9y4UgeWtEogNXw-aRICBGToVYSvxEQs.pad7fO5N5-OylEJd8dyZU71iFj2iceOyVmBROR_GQ23o9SUo1WDwwZe8XQ~c064214033a6822961048d73b7963616

Analyst Recommendations on Neuronetics, Inc.

William Blair Upgrades Neuronetics to Outperform From Market Perform MT
Canaccord Genuity Adjusts Price Target on Neuronetics to $7 From $9, Maintains Buy Rating MT
Piper Sandler Adjusts Neuronetics' Price Target to $9 From $10, Reiterates Overweight Rating MT
NEURONETICS : JMP Securities Adjusts Price Target on Neuronetics to $12 From $18, Maintains Market Outperform Rating MT
NEURONETICS : William Blair Downgrades Neuronetics to Market Perform From Outperform MT
NEURONETICS : BTIG Downgrades Neuronetics to Neutral from Buy MT
NEURONETICS : William Blair Upgrades Neuronetics to Outperform From Market Perform MT
NEURONETICS : Piper Sandler Adjusts Neuronetics' Price Target to $27 from $20, Keeps Overweight Rating MT
NEURONETICS : BTIG Research Adjusts Neuronetics PT to $21 From $14, Maintains Buy Rating MT
NEURONETICS : BTIG Research Adjusts Neuronetics PT to $14 From $10, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.92 USD
Average target price
7 USD
Spread / Average Target
+264.58%
High Price Target
8 USD
Spread / Highest target
+316.67%
Low Price Target
6 USD
Spread / Lowest Target
+212.50%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Neuronetics, Inc.

William Blair & Co.
Canaccord Genuity
Piper Sandler
JMP Securities
BTIG

Ratings for Neuronetics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. STIM Stock
  4. Consensus Neuronetics, Inc.